News

Industry leaders share their sources of inspiration.

Pharmaceutical manufacturer relationships and next-gen value based contracts are primed to accelerate value-derivation from your drug spend.

Experts share their ideas on how President-elect Trump could change the single largest source of insurance in the country.

In the aftermath of the presidential election, health policy experts have less to go on than they have after any election in memory.

“Repeal and replace” or “replace and improve” activities on The Hill, though not “business as usual,” won’t necessary slow down data-driven focus areas in healthcare that will continue in 2017.

FDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.

Results from Managed Healthcare Executive’s annual State of the Industry Survey reveal which issues will hit managed healthcare hardest in 2017.

We have a path to ending the HIV epidemic in the United States, but it requires health plans and healthcare purchasers to take a more active role in getting us there.

The US growth rate for spending on medicines is expected to fall in 2016 and beyond, according to new research.

President-elect Trump named Tom Price and Seema Verma to lead HHS and CMS, respectively. Here’s what you should know about them.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

Investigational gene therapies might reduce the suffering and death caused by this genetic disease.

As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care-and discussing how to efficiently share the massive amounts of genomic data that will result.

CMS is adding, dropping, and expanding payment rules

Hospitals and health systems that treat some of the country’s most vulnerable populations face complex challenges when working to improve population health.

None of Trump’s plans, such as repealing parts of Obamacare or expanding HSAs, will rein in the rising cost of healthcare.

There now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study

FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion.

Plans and PBMs are finding new ways to rein in pharmacy costs.

Telephonic and personalized diabetes self-education programs which fit into patient’s busy lives will make a greater impact than in-person classes only.

In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.

Will President-elect Donald Trump affect the outcome of the Anthem-Cigna and Aetna-Humana mergers?

An ASH presenter describes how better health IT and better institutional practices are necessary to leverage EHRs for quality of care.

Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.

Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.

Joint ventures are gaining steam as health plans and providers look for new ways to work together.

Two new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.

Two experts discuss top-of-mind women’s healthcare issues in managed care.